Application status of endoscopic anti-reflux mucosal interventions in the treatment of gastroesophageal reflux disease

Table 8 Incidence of postoperative dysphagia and related complications following anti-reflux ablation therapy and peroral endoscopic cardial constriction

Ref.	Year	Intervention	Cases	Incidence of adverse events (%)
				Stenosis or dysphagia	Relief after dilatation	Bleeding	Perforation
Inoue et al[19]	2020	ARMA	8	12.5	Yes	0.0	0.0
Hernández Mondragón et al[20]	2020	ARAT	108	13.0	Yes	0.0	0.0
Chou et al[22]	2023	ARMA	12	8.3	Yes	8.3	0.0
Shimamura et al[23]	2024	ARMA	68	13.2	Yes	8.8	0.0
Klimczak et al[24]	2023	ARMA	10	0.0	NA	0.0	0.0
Average				9.40		3.42	0.0
Li et al[25]	2017	PECC	47	4.3	No	4.3	0.0
Liu et al[26]	2020	C-BLART	60	5.0	No	0.0	0.0
Seleem et al[27]	2018	EBL	75	25.3	No	0.0	0.0
Li et al[28]	2021	PECC-b	68	41.2	No	2.9	0.0
Jiang et al[29]	2022	PECC-b	16	12.5	No	12.5	0.0
Deshmukh et al[30]	2022	ARBM	4	0.0	NA	0.0	0.0
Hu et al[34]	2018	PECC	13	0.0	NA	0.0	0.0
Wang et al[39]	2020	PECC	15	40.0	No	0.0	0.0
Average				16.04		2.46	0.0

ARMA: Anti-reflux mucosal ablation; ARAT: Anti-reflux ablation therapy; PECC: Peroral endoscopic cardial constriction; EBL: Endoscopic band ligation; C-BLART: Clip band ligation anti-reflux therapy; PECC-b: Peroral endoscopic cardial constriction with band ligation; ARBM: Anti-reflux band mucosectomy; NA: Not available.